Methods for treating cancer
AssigneeX4 Pharmaceuticals, Inc.
InventorRobert D. Arbeit
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating patients with advanced forms of cancer, such as unresectable or metastatic renal cell carcinoma or kidney cancer, in which X4P-001 or a pharmaceutically acceptable salt thereof is administered as monotherapy or in combination with an immune checkpoint inhibitor, such as nivolumab. The methods demonstrate surprising results, including regression of disease, with comparatively little toxicity.
Claims21
A method for treating cancer in a patient in need thereof, wherein said method comprises administering to said patient X4P-001 or a pharmaceutically acceptable salt thereof in combination with an immune checkpoint inhibitor.
A method for increasing responsiveness to treatment with an immune checkpoint inhibitor in a patient receiving said treatment, said method comprising administering to said patient X4P-001 or a pharmaceutically acceptable salt thereof in an amount effective to increase CD8+ T cell density.
A unit dosage form comprising a composition comprising:
- (a) X4P-001, or a pharmaceutically acceptable salt thereof—about 30-40% by weight of the composition;
- (b) microcrystalline cellulose—about 20-25% by weight of the composition;
- (c) dibasic calcium phosphate dehydrate—about 30-35% by weight of the composition;
- (d) croscarmellose sodium—about 5-10% by weight of the composition;
- (e) sodium stearyl fumarate—about 0.5-2% by weight of the composition;
- (f) colloidal silicon dioxide—about 0.1-1.0% by weight of the composition;
- and
- (g) sodium lauryl sulfate—about 0.1-1.0% by weight of the composition.
Dependencies are inferred from the claim text.